1 | 150 mg double-blinded secukinumab (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
2 | 150 mg open-label secukinumab (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
3 | 300 mg double-blinded secukinumab (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
4 | Cosentyx | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [4] 41 41, 107, 269, 271 💬
|
5 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 107 107 💬
|
6 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 107 107 💬
|
7 | Cosentyx 300 mg solution for injection in pre-filled syringe | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 41 41 💬
|
8 | Cosentyx 300mg solution for injection in pre-filled syringe | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 41 41 💬
|
9 | Cosentyx® | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 269 269 💬
|
10 | SECUKINUMAB (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [8] 13 13, 37, 41, 46, 107, 160, 269, 271 💬
|
11 | Secukinumab (150 mg) (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
12 | Secukinumab (75 mg) (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
13 | Secukinumab (AIN457) (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 46 46 💬
|
14 | Secukinumab (AIN457) 150 mg s.c. (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
15 | Secukinumab 150 mg (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 41 41 💬
|
16 | Secukinumab 150 mg (2 injections per dose (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 269 269 💬
|
17 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
18 | Secukinumab 150 mg/1 ml Solution for injection (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [2] 37 37, 271 💬
|
19 | Secukinumab 150 mg/ml (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
20 | Secukinumab 150 milligram [Cosentyx] | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
21 | Secukinumab 150mg (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 37 37 💬
|
22 | Secukinumab 300 mg (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 41 41 💬
|
23 | Secukinumab 300 mg, s.c. (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 41 41 💬
|
24 | Secukinumab 300mg (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 37 37 💬
|
25 | Secukinumab 75 mg/0.5 ml Solution for injection (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
26 | Secukinumab Injection (Cosentyx (TN)) | [1] Secukinumab Secukinumab (Cosentyx) | [1] Secukinumab
Secukinumab
(Cosentyx (TN)) 💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 160 160 💬
|